Trusted Resources: Education
Scientific literature and patient education texts
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type A
source: Molecular genetics and metabolism
year: 2021
authors: Wijburg FA,Heap F,Rust S,de Ruijter J,Tump E,Marchal JP,Nestrasil I,Shapiro E,Jones SA,Alexanderian D
summary/abstract:Currently, there is no effective therapy for mucopolysaccharidosis IIIA (MPS IIIA). Intravenously-administered enzyme replacement therapies, while effective in other forms of MPS without neurological involvement, have not been successful in patients with MPS IIIA, as they are unable to cross the blood-brain barrier to improve neurological symptoms. We evaluated the long-term safety, tolerability, and clinical outcomes of recombinant human heparan-N-sulfatase (rhHNS) administered intrathecally (IT) in children with MPS IIIA in a phase 1/2 extension study.
organization: Amsterdam UMC, University of Amsterdam, Pediatric Metabolic Diseases, Emma Children's Hospital and Amsterdam Lysosome Center "Sphinx", Amsterdam, the Netherlands. Electronic address: [email protected].DOI: 10.1016/j.ymgme.2021.09.003
read more
Related Content
-
I Want to Live in the Moment While There’s Still TimeMy daughter Abby has Sanfilippo syndrome...
-
Mucopolysaccharidosis Type III – Sanfilippo SyndromeMucopolysaccharidosis type III (MPS III)...
-
Believe in G Golf TournamentGianna, was diagnosed with Sanfilippo Sy...
-
New Type A ERT Candidate on Track for Clinical TrialJapanese company, JCR Pharmaceuticals, h...
-
Developing a Treatment Plan for Sanfilippo SyndromeSanfilippo syndrome is a neurodegenerati...
-
Significant Neuropsychiatric Symptoms: Three Mucopolysaccharidosis Type IIIB Cases, Two of Whom Were Siblings With a...Mucopolysaccharidosis (MPS) type IIIB pa...
-
A Guide to Understanding MPS III (Sanfilippo Syndrome)MPS III belongs to a group of inherited ...